Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karen Van Malderen
Observed name:
Karen van Malderen
Institution:
European Medicines Agency
Observed institution:
European Medicines Agency
OpenAlex ID:
A5005031518
Use of paracetamol during pregnancy and child neurological development
2015
·
Laurence de Fays
, Karen Van Malderen
, et al.
·
Developmental Medicine & Child Neurology
·
68
PDF
European regulatory strategy for supporting childhood cancer therapy developments
2022
·
Dominik Karres
, Giovanni Lesa
, et al.
·
European Journal of Cancer
·
20
PDF
The benefits, limitations and opportunities of preclinical models for neonatal drug development
2022
·
Sarah Campion
, Amy Inselman
, et al.
·
Disease Models & Mechanisms
·
11
PDF
Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective
2019
·
Jan Willem van der Laan
, Karen van Malderen
, et al.
·
International Journal of Toxicology
·
11
PDF
From guideline to practice: three years of ICH S11 insights and recommendations
2025
·
Diana Tavares
, Hsiao-Tzu Chien
, et al.
·
Frontiers in Medicine
·
4
PDF
Translating non-clinical proof-of-concept data into paediatric development decisions: the case of HER2-targeting antibody-drug conjugates
2026
·
Pauliina Lehtolainen-Dalkilic
, Caoimhin G. Concannon
, et al.
·
EJC Paediatric Oncology
PDF
Integrating non-clinical and clinical evidence for prioritisation in paediatric oncology drug development: Regulatory experience with three PARP inhibitors
2026
·
Karen Van Malderen
, Sofie Peirs
, et al.
·
EJC Paediatric Oncology
PDF
Show more works
View as search
Works count:
7
Citation count:
114
H-index:
4
I10-index:
4
Year
Topic
Type